Remove Clinical Development Remove Immune Response Remove Small Molecule
article thumbnail

Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses

The Pharma Data

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

article thumbnail

Novel nasal spray reduces COVID-19 viral replication in animal study

The Pharma Data

It is a synthetic small molecule that would be self-administered via nasal spray, taken once or twice a week for the prevention of COVID-19. from Australian investors to progress the INNA-051 clinical development programme. So far, Ena has raised AU$11.7m We’ve been amazed with just how effective our treatment has been.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New targeted therapies show promise in lung cancer treatment

Drug Target Review

7,8 The discovery of these biomarkers provides valuable insights into prognosis and disease progression, while also guiding the clinical development of new targeted immunotherapies. Engineering sites on the antibody to enable specific and consistent attachment of the cytotoxic drug to achieve an optimal drug-to-antibody ratio (DAR).

article thumbnail

BioNTech announces first patient dosed in Phase 2 clinical trial of mRNA-based BNT111 in patients with advanced melanoma

The Pharma Data

BNT111 is the lead product candidate from BioNTech’s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immune response against cancer and is fully owned by BioNTech. About FixVac. About BioNTech.

article thumbnail

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock – Oct 28, 2020

The Pharma Data

Mirati is advancing a novel pipeline to treat large patient populations across multiple programs and tumor types, including two programs, adagrasib and sitravatinib, in registration-enabling studies to treat non-small cell lung cancer (NSCLC).

article thumbnail

Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors

The Pharma Data

(Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel’s R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases. vice president of immunology at Lilly. About Rigel.

article thumbnail

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera

The Pharma Data

The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Both programs have the potential to address multiple indications, offering broad development opportunities alone and in combination with Gilead’s portfolio.